<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514694</url>
  </required_header>
  <id_info>
    <org_study_id>LP0058-1114</org_study_id>
    <nct_id>NCT02514694</nct_id>
  </id_info>
  <brief_title>LEO 32731 - A Phase I Study in Healthy Subjects</brief_title>
  <official_title>LEO 32731 - A Phase I, Single-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <brief_summary>
    <textblock>
      LEO 32731 (&quot;Study Drug&quot;) is an investigational drug which is being developed by LEO Pharma&#xD;
      A/S (&quot;the Sponsor&quot;) for treatment of psoriasis. The aim (s) of this Study are to determine:&#xD;
&#xD;
        -  The safety and tolerability of the Study Drug and any side effects that might be&#xD;
           associated with it&#xD;
&#xD;
        -  The Study will also measure how much of the Study Drug that gets into the blood and how&#xD;
           long time it takes for the body to remove it.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety reported as number of Participants with Adverse Events</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics reported as area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 32731</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO32731</intervention_name>
    <arm_group_label>LEO 32731</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Subjects will, prior to any study related activities, have given their written&#xD;
             informed consent to participate in the study and to abide by the study restrictions.&#xD;
&#xD;
          -  2. Subjects will be males or females of non-childbearing potential between 18 and 55&#xD;
             years of age.&#xD;
&#xD;
          -  3. Subjects will have a body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive.&#xD;
&#xD;
          -  4. For Group C, subjects will be women of non-childbearing potential.&#xD;
&#xD;
          -  5. Subjects must be in good health.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Male subjects who are not willing, or whose partners are not willing, to use&#xD;
             appropriate contraception.&#xD;
&#xD;
          -  2. Subjects who have received any prescribed systemic or topical medication within 14&#xD;
             days of the first dose administration unless in the opinion of the Investigator the&#xD;
             medication will not interfere with the study procedures or compromise safety.&#xD;
&#xD;
          -  3. Subjects who have used any non-prescribed systemic or topical medication (including&#xD;
             herbal remedies) within 7 days of the first dose administration unless in the opinion&#xD;
             of the Investigator the medication will not interfere with the study procedures or&#xD;
             compromise safety.&#xD;
&#xD;
          -  4. Subjects who have received any medications, including St John's Wort (or other&#xD;
             dietary restriction, Section 6.2.3), known to chronically alter drug absorption or&#xD;
             elimination processes within 30 days of the first dose administration unless in the&#xD;
             opinion of the Investigator the medication will not interfere with the study&#xD;
             procedures or compromise safety.&#xD;
&#xD;
          -  5. Subjects with a significant history of drug allergy as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  6. Subjects who have any clinically significant allergic disease (excluding non-active&#xD;
             hayfever) as determined by the Investigator.&#xD;
&#xD;
          -  7. Subjects who have a supine blood pressure and supine pulse rate at screening higher&#xD;
             than 140/90 mmHg and 100 beats per minute (bpm), respectively, or lower than 90/50&#xD;
             mmHg and 50 bpm, respectively.&#xD;
&#xD;
          -  8. Subjects with a positive urine drug screen or alcohol breath test result at&#xD;
             screening or first admission.&#xD;
&#xD;
          -  9. Subjects with, or with a history of, any clinically significant neurological,&#xD;
             gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic,&#xD;
             endocrine, haematological, dermatological or other major disorders as determined by&#xD;
             the Investigator.&#xD;
&#xD;
          -  10. Subjects who have had a clinically significant illness within 4 weeks of the start&#xD;
             of dose administration as determined by the Investigator.&#xD;
&#xD;
          -  11. Subjects who are known to have serum hepatitis, or who are carriers of the&#xD;
             hepatitis B surface antigen (HBsAg) or hepatitis C antibody, or who have a positive&#xD;
             result to the test for HIV antibodies.&#xD;
&#xD;
          -  12. Active tuberculosis or history of incompletely treated tuberculosis, based on&#xD;
             medical history or medical report.&#xD;
&#xD;
          -  13. Subjects who, in the opinion of their General Practitioner (GP) or the&#xD;
             Investigator, should not participate in the study.&#xD;
&#xD;
          -  14. Subjects with one or more positive faecal occult blood test (immunochemical&#xD;
             method) out of 2 assessments at the time between screening and Day-1 check-in.&#xD;
&#xD;
          -  15. Subjects with â‰¥ 3 bowel movements/day.&#xD;
&#xD;
          -  16. Subjects who have previously taken part in or withdrawn from this study.&#xD;
&#xD;
          -  17. Subjects who, in the opinion of the Investigator, should not participate in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance CRU</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

